Father's Day Sale! Save 25%
Free Express Shipping
Sale Ends: 06/16
Uses
Side effects
Interactions
Precautions
What Haldol is used for:
- HALDOL is indicated for use in the treatment of schizophrenia. It can treat certain types of mental disorders.
- HALDOL is indicated for the control of tics and vocal utterances of Tourette’s Disorder.
- Dizziness, lightheadedness, drowsiness, difficulty urinating, sleep disturbances, headache, and anxiety may occur.
- If these effects last or get worse, notify your doctor or pharmacist promptly.
- Dizziness and lightheadedness can increase the risk of falling. Get up slowly when rising from a sitting or lying position.
- Since QT-prolongation has been observed during HALDOL treatment, caution is advised when prescribing to a patient with QT-prolongation conditions (long QT-syndrome, hypokalemia, electrolyte imbalance) or to patients receiving medications known to prolong the QT-interval or known to cause electrolyte imbalance.
- As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol. Ketoconazole is a potent inhibitor of CYP3A4. Increases in QTc have been observed when haloperidol was given in combination with the metabolic inhibitors ketoconazole (400 mg/day) and paroxetine (20 mg/day). It may be necessary to reduce the haloperidol dosage.
- Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of HALDOL should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.
- Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm3 ) should discontinue HALDOL and have their WBC followed until recovery.
